Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Science ; 169(3952): 1320-1, 1970 Sep 25.
Artículo en Inglés | MEDLINE | ID: mdl-4247738

RESUMEN

We have identified propiololdehyde as a product of the action of an electric discharge on mixtures of methane and water or methane, nitrogen, and water. The aldehyde reacts with cyanoacetaldehyde and ammonia (other "prebiological molecules") to yield nicotinonitrile. This substance can be hydrolyzed to nicotinamide and nicotinic acid.


Asunto(s)
Aldehídos/síntesis química , Niacinamida/síntesis química , Nitrilos/síntesis química , Piridonas/síntesis química , Amoníaco , Barbitúricos , Cromatografía por Intercambio Iónico , Electricidad , Concentración de Iones de Hidrógeno , Metano , Ácidos Nicotínicos
2.
Trans R Soc Trop Med Hyg ; 95(4): 429-32, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11579890

RESUMEN

Plasmodia infect the liver for about 7 days before subsequently infecting the blood. Present prophylaxis against Plasmodium falciparum malaria employs agents that primarily kill blood stages and must be continued for 28 days after the last exposure. Atovaquone-proguanil (Malarone) is a new antimalarial agent that is licensed in 35 countries as treatment against blood-stage infection, but its components (atovaquone and proguanil) have separately been shown to be active also against liver stages. To determine whether atovaquone-proguanil is sufficiently active against liver stages to be discontinued 7 days after exposure, we challenged 16 volunteers with P. falciparum via infected mosquitoes. Twelve volunteers received atovaquone-proguanil (1 tablet daily) on the day prior to challenge, on the day of challenge, and for the next 6 days; 4 volunteers received matching placebo. All placebo volunteers demonstrated parasitaemia and malarial symptoms beginning on days 11-12 after challenge. No atovaquone-proguanil volunteer acquired malaria. Atovaquone-proguanil is the first licensed antimalarial agent that kills P. falciparum in the liver and that may be discontinued 7 days after the last exposure.


Asunto(s)
Antimaláricos/uso terapéutico , Parasitosis Hepáticas/tratamiento farmacológico , Malaria Falciparum/prevención & control , Naftoquinonas/uso terapéutico , Proguanil/uso terapéutico , Adolescente , Adulto , Atovacuona , Método Doble Ciego , Combinación de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Naftoquinonas/farmacocinética , Proguanil/farmacocinética , Resultado del Tratamiento
3.
Plant Physiol ; 53(2): 229-32, 1974 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-16658681

RESUMEN

The possibility of an auxin effect on the permeability of pea (Pisum sativum L. ev. Alaska) segments to tritium-labeled water has been investigated by three separate laboratories, and the combined results are presented. We were unable to obtain any indication of a rapid effect of indoleacetic acid on the efflux of (3)HHO when pea segments previously "loaded" for 90 minutes with (3)HHO were transferred to unlabeled aqueous medium with indoleacetic acid. We were able to confirm that segments pretreated with (3)HHO plus indoleacetic acid for 60 to 90 minutes can show an enhanced (3)HHO release as compared with minus indoleacetic acid controls. However, this phenomenon appears to be due to an increased uptake of (3)HHO during the prolonged indoleacetic acid pretreatment, and therefore we conclude that auxin does not alter the permeability of pea segments to (3)HHO in either short term or long term tests. We confirm previous reports that the uptake of (3)HHO in pea segments proceeds largely through the cut surfaces, and that the cuticle is a potent barrier to (3)HHO flux.

4.
Orig Life ; 8(3): 221-4, 1977 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-600509

RESUMEN

It is hypothesized that there is a close relationship between the geologic evolution of the global plates of the Earth's crust and the chemical evolution of life on the Earth. Characteristics of the axes of plate spreading are discussed in relation to postulated environments conductive to the synthesis of chemical compounds thought to be important biological precursors. Likely locations for in situ measurements to test the hypothesis are identified.


Asunto(s)
Origen de la Vida , Evolución Biológica , Fenómenos Geológicos , Geología
5.
Trop Anim Health Prod ; 21(1): 4-10, 1989 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-2711462

RESUMEN

Various chemotherapeutic regimes were used to control trypanosomiasis in 3,000 Boran cattle on an estate on the Kenya coast. Recently the therapeutic use of isometamidium by the intravenous route was adopted to treat individual trypanosome-infected cattle. This was in order to overcome tissue reactions encountered after intramuscular injection and also to control a "thin cow" syndrome attributed to chronic trypanosomiasis. Toxic side effects were eliminated by careful attention to the intravenous technique which was safely used in calves, pregnant cattle and bulls. Weekly blood sampling and treatments of infected individuals resulted in a reduction of cases from 2,187 to 208 out of 46,495 and 46,329 samples examined in 1985 and 1986 respectively. The standard of management was very high and although this routine successfully controlled bovine trypanosomiasis on this estate its application elsewhere is likely to be limited.


Asunto(s)
Enfermedades de los Bovinos/tratamiento farmacológico , Fenantridinas/uso terapéutico , Tripanocidas/uso terapéutico , Tripanosomiasis Bovina/prevención & control , Animales , Peso al Nacer , Bovinos , Enfermedades de los Bovinos/epidemiología , Femenino , Inyecciones Intravenosas/veterinaria , Kenia , Masculino , Fenantridinas/administración & dosificación , Fenantridinas/efectos adversos , Embarazo , Factores de Riesgo , Tripanocidas/administración & dosificación , Tripanocidas/efectos adversos , Tripanosomiasis Africana/tratamiento farmacológico , Tripanosomiasis Africana/prevención & control , Tripanosomiasis Africana/veterinaria , Tripanosomiasis Bovina/tratamiento farmacológico , Tripanosomiasis Bovina/epidemiología , Moscas Tse-Tse
6.
Plant Physiol ; 53(2): 224-8, 1974 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-16658680

RESUMEN

Several cell wall-bound glycosidases present in Avena sativa coleoptiles were assayed by following the hydrolysis of p-nitrophenyl-glycosides. Particular emphasis was placed on characterizing some parameters affecting the activity of beta-galactosidase. The pH optimum of this enzyme is 4.5 to 5.5; it is sensitive to copper ions and p-chloromercuribenzoate treatment and apparently has an exceptionally low turnover rate. Indoleacetic acid treatment enhanced in vivo beta-galactosidase activity of coleoptile segments by 36% over control after 60 minutes. This enhancement was prevented by abscisic acid and cycloheximide. High buffer strengths and low pH reduced the indoleacetic acid-enhanced increase in enzyme activity. These data lend support to the following proposed model of indoleacetic acid action. Indoleacetic acid enhances the release of hydrogen ions into the cell wall which promote the activities of cell wall glycosidases, some of which may participate in the cell extension process.

7.
J Infect Dis ; 183(4): 640-7, 2001 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-11170991

RESUMEN

After initial successful evaluation of the circumsporozoite-based vaccine RTS,S/SBAS2, developed by SmithKline Beecham Biologicals with the Walter Reed Army Institute of Research, protective efficacy of several regimens against Plasmodium falciparum challenge was determined. A controlled phase 1/2a study evaluated 1 or 2 standard doses of RTS,S/SBAS2 in 2 groups whose members received open-label therapy and 3 immunizations in blinded groups who received standard, one-half, or one-fifth doses. RTS,S/SBAS2 was safe and immunogenic in all groups. Of the 41 vaccinees and 23 control subjects who underwent sporozoite challenge, malaria developed in 7 of 10 who received 1 dose, in 7 of 14 who received 2 doses, in 3 of 6 who received 3 standard doses, in 3 of 7 who received 3 one-half doses, in 3 of 4 who received 3 one-fifth doses, and in 22 of 23 control subjects. Overall protective efficacy of RTS,S/SBAS2 was 41% (95% confidence interval, 22%-56%; P=.0006). This and previous studies have shown that 2 or 3 doses of RTS,S/SBAS2 protect against challenge with P. falciparum sporozoites.


Asunto(s)
Vacunas contra la Malaria , Malaria Falciparum/prevención & control , Plasmodium falciparum/inmunología , Proteínas Protozoarias/inmunología , Adolescente , Adulto , Animales , Anticuerpos Antiprotozoarios/sangre , Femenino , Humanos , Activación de Linfocitos , Vacunas contra la Malaria/administración & dosificación , Vacunas contra la Malaria/efectos adversos , Vacunas contra la Malaria/inmunología , Masculino , Persona de Mediana Edad , Proteínas Protozoarias/genética , Proteínas Recombinantes/inmunología , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/inmunología
8.
J Infect Dis ; 178(4): 1139-44, 1998 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-9806046

RESUMEN

The malaria sporozoite vaccine candidate RTS,S, formulated with an oil-in-water emulsion plus the immunostimulants monophosphoryl lipid A and the saponin derivative QS21 (vaccine 3), recently showed superior efficacy over two other experimental formulations. Immunized volunteers were followed to determine the duration of protective immune responses. Antibody levels decreased to between one-third and one-half of peak values 6 months after the last dose of vaccine. T cell proliferation and interferon-gamma production in vitro were observed in response to RTS,S or hepatitis B surface antigen. Seven previously protected volunteers received sporozoite challenge, and 2 remained protected (1/1 for vaccine 1, 0/1 for vaccine 2, and 1/5 for vaccine 3). The prepatent period was 10.8 days for the control group and 13.2 days for the vaccinees (P < .01). Immune responses did not correlate with protection. Further optimization in vaccine composition and/or immunization schedule will be required to induce longer-lasting protective immunity.


Asunto(s)
Vacunas contra la Malaria/inmunología , Malaria Falciparum/prevención & control , Vacunación , Adolescente , Adulto , Anticuerpos Antiprotozoarios/sangre , Supervivencia sin Enfermedad , Humanos , Interferón gamma , Persona de Mediana Edad , Proteínas Protozoarias/inmunología , Linfocitos T/inmunología , Vacunas Sintéticas/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA